Brandenburg Tim, Machlah Yara Maria, Führer Dagmar
Klinik für Endokrinologie, Diabetologie und Stoffwechsel, Universitätsklinikum Essen, Essen, Deutschland.
Endokrines Tumorzentrum am Westdeutschen Tumorzentrum (WTZ), Universitätsklinikum Essen, Universität Duisburg-Essen, Member of Endo-ERN und EURACAN, Essen, Deutschland.
Inn Med (Heidelb). 2024 Mar;65(3):202-210. doi: 10.1007/s00108-023-01635-6. Epub 2024 Jan 17.
Medullary thyroid cancer (MTC) is a prime example for precision medicine in endocrinology and underlines the immediate benefits of basic, translational and healthcare research for patients with a rare disease in clinical . A mutation in the rearranged during transfection (RET) proto-oncogene that codes for a transmembrane receptor protein tyrosine kinase, leads to constitutive activation of the kinase, which is the decisive pathomechanism for the disease. The MTC occurs in a sporadic (somatic RET mutation) or hereditary form (RET germline mutation, multiple endocrine neoplasia types 2 and 3). For germline mutation carriers the timing of preventive thyroidectomy depends on the RET genotype. For advanced metastasized RET-mutant MTC, selective RET kinase inhibitors are available, which are currently considered to be game changers in the treatment. Based on the specific tumor marker calcitonin, MTC can be identified at an early stage during the differential diagnosis of thyroid nodules. The preoperative calcitonin level even enables statements on the degree of dissemination of the disease and on the probability of a cure through surgery. A new development is the consideration of desmoplasia as a histopathological biomarker for the metastatic potential of a MTC, which could possibly modify the operative approach as well as the future MTC nomenclature. Furthermore, the postoperative calcitonin level and the calcitonin doubling time are highly valid prognostic markers for tumor burden and biological aggressiveness of MTC and therefore decisive for patient follow-up. Biochemical, molecular and histological markers enable a risk-adapted surgical treatment and together with new targeted systemic treatments have contributed to a paradigm shift in the diagnostics, prognosis and treatment of MTC in recent years. Endocrine precision medicine for MTC therefore enabled a change from the previous purely symptom-oriented to a modern preventive and individualized treatment.
甲状腺髓样癌(MTC)是内分泌学中精准医学的一个典型例子,突显了基础研究、转化研究和医疗保健研究对临床罕见病患者的直接益处。转染重排(RET)原癌基因发生突变,该基因编码一种跨膜受体蛋白酪氨酸激酶,会导致激酶的组成性激活,这是该疾病的决定性发病机制。MTC以散发性(体细胞RET突变)或遗传性形式(RET种系突变,2型和3型多发性内分泌肿瘤)出现。对于种系突变携带者,预防性甲状腺切除术的时机取决于RET基因型。对于晚期转移性RET突变型MTC,有选择性RET激酶抑制剂可用,目前这些抑制剂被认为是治疗中的变革者。基于特异性肿瘤标志物降钙素,在甲状腺结节的鉴别诊断早期即可识别MTC。术前降钙素水平甚至能够判断疾病的扩散程度以及通过手术治愈的可能性。一个新的进展是将促纤维增生反应视为MTC转移潜能的组织病理学生物标志物,这可能会改变手术方式以及未来MTC的命名。此外,术后降钙素水平和降钙素倍增时间是MTC肿瘤负荷和生物学侵袭性的高度有效的预后标志物,因此对患者随访至关重要。生化、分子和组织学标志物能够实现风险适应性手术治疗,并且与新的靶向全身治疗一起,近年来促成了MTC诊断、预后和治疗的范式转变。因此,MTC的内分泌精准医学实现了从以往单纯以症状为导向到现代预防性和个体化治疗的转变。